Highest-materiality recent filing
Amylyx stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting
Elected George Mclean Milne Jr., Ph.D. (76.9M for, 14.1M withheld) and Paul Fonteyne (86.3M for, 4.8M withheld) as Class II directors.
Amylyx Q1 net loss $41.3M; Phase 3 avexitide topline data in Q3 2026
Net loss of $41.3M ($0.37 per share) vs $35.9M ($0.42) in Q1 2025; cash used in operations.
Completed enrollment in Phase 3 LUCIDITY trial.
Net loss for FY2025: $144.7M ($1.53/share) vs $301.7M ($4.43/share) in FY2024.
Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia
AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.
Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering
Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.
Amylyx launches $164M common stock offering at $10.00 per share to fund avexitide launch
Offering of 17.5M shares (2.625M option) at $10.00/share; net proceeds ~$164M, up to ~$188.7M.
Amylyx discontinues AMX0035 program for PSP after Phase 2b miss
AMX0035 failed to show differences vs placebo on primary or secondary outcomes at Week 24.
Amylyx Q2 net loss narrows to $41.4M; cash $180.8M; pipeline milestones on track
Net loss of $41.4M ($0.46 per share) vs $72.7M ($1.07) in Q2 2024; lower SG&A and R&D spend in ALS.
Amylyx shareholders elect three Class I directors; ratify Deloitte; approve say-on-pay proposal
Karen Firestone, Justin Klee, and Bernhardt Zeiher elected as Class I directors for term ending 2028. Firestone and Zeiher each had ~21.3M votes withheld; Klee had 1.5M.
Amylyx Q1 net loss $35.9M, cash $204.1M; avexitide Phase 3 underway
Q1 net loss $35.9M ($0.42/share), down from $118.8M ($1.75/share) YoY on lower R&D and SG&A costs.
Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise
Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).
Amylyx prices 17.1M-share public offering at $3.50/sh for ~$56.9M net proceeds
Offering of 17,142,857 common shares at $3.50 per share, with 30-day option for up to 2,571,428 additional shares.
Amylyx and Gubra collaborate on GLP-1 antagonist; milestones up to >$50M
Collaboration with Gubra to develop a novel long-acting GLP-1 receptor antagonist; Amylyx to make small upfront and research payments (not material).
Amylyx reports Q3 net loss of $72.7M; cash $234.4M; pipeline updates on AMX0035, avexitide, AMX0114
Net loss of $72.7M ($1.07 loss per share) vs net income of $20.9M in Q3 2023; acquired IPR&D expense of $36.2M for avexitide.
HELIOS Phase 2: AMX0035 improves C-peptide AUC by +3.8 min*ng/mL at Week 24 in Wolfram syndrome
Primary endpoint: C-peptide AUC improved at Week 24 (ITT +3.8 min*ng/mL; Per Protocol +20.2) and sustained through Week 48 (+36.7).
Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition
Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.
Amylyx completes acquisition of Avexitide from Eiger for $35.1M
Acquired Avexitide from Eiger BioPharmaceuticals for $35.1 million plus cure costs and assumed liabilities.
Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M
Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.
Amylyx shareholders elect Cohen, Quimi as directors; ratify Deloitte
Joshua Cohen and Daphne Quimi elected as Class III directors with ~32.6M and ~32.5M votes for, respectively.
Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M
Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.
Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)
C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.
Amylyx pulls RELYVRIO from market after Phase 3 miss, cuts 70% of staff
Voluntarily discontinues RELYVRIO/ALBRIOZA in U.S. and Canada; no new patients after today.
Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy
Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.
Amylyx Phase 3 ALS trial misses primary endpoint; may withdraw RELYVRIO
PHOENIX trial: no significant difference on ALSFRS-R at Week 48 (p=0.667); secondary endpoints also missed.
On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director
Max materiality 1.00 · Median 0.65 · Most common event other_material